Zhang et al. identified four plasma EV-derived proteins (ARG1/CD3/PD-L1/PD-L2) as an EV-score that robustly predicts immunotherapeutic outcomes at baseline and monitors disease progression with ICI treatment in GC patients [91]. The gene discussed is CD274; the disease is gastric cancer.